The strategic investments of DEMO S.A., Win Medica (ELPEN Group), and FARAN in Tripoli were visited today, Thursday, June 25, 2026, the Deputy Prime Minister and Member of Parliament for the Northern Athens Constituency, Mr. Kostis Hatzidakis, and the Secretary of the New Democracy Political Committee and Member of Parliament for the Southern Athens Constituency, Mr. Konstantinos Kyranakis. Also present during the visits was Mr. Kostas Vlasis, Deputy Minister of Education, Religious Affairs, and Sports and Member of Parliament for Arcadia.
The two government representatives were given a tour of the companies’ production facilities and received detailed briefings on the progress of the investment projects, the technological infrastructure, and the strategic development plans for the plants in Tripoli.
The investments currently underway are projects of strategic importance for strengthening the country’s production autonomy, ensuring an adequate supply of pharmaceuticals, and enhancing Greece’s position within the European ecosystem of pharmaceutical production, research and innovation.
The development of modern production facilities and research infrastructure strengthens the domestic production base for critical pharmaceutical products, reduces dependence on imports, thereby minimizing shortages, and shields the national health system from international disruptions in the supply chain.
In particular, investments in Tripoli by DEMO, Win Medica (ELPEN Group), and FARAN, totaling more than 400 million euros, mark a new era for the country’s industrial reconstruction and the strengthening of the Greek economy’s resilience. With these investments, it is estimated that over the next few years, more than 30% of European citizens’ needs in these specific therapeutic categories will be met.
During the visit, key aspects of the investments were highlighted, such as the development of active pharmaceutical ingredient production on an industrial scale—a first for the country— the strengthening of research and innovation, as well as the creation of more than 1,500 direct and indirect highly specialized jobs. These investments contribute significantly to regional development and create strong incentives for highly qualified scientific personnel to return to Greece.
The Deputy Prime Minister and Member of Parliament for the Northern Athens District, Mr. Kostis Hatzidakis, stated: “Here, in the Tripoli Industrial Area, two myths are being debunked: that the country’s industry is not moving forward and that the government does not prioritize regional development. We visited three new, state-of-the-art pharmaceutical plants.
These investments create jobs and are export-oriented, contributing to the region’s productive growth. At the same time, they attract new employees, and in collaboration with the Ministry of Education, the pharmaceutical companies have established the first Pharmaceutical Academy, bringing the local community closer to the industry and creating very positive prospects for young people.”
The Secretary of the New Democracy Policy Committee and Member of Parliament for the Southern Athens District, Mr. Konstantinos Kyranakis, stated: “The most encouraging message from our visit today to the new investments by the Greek pharmaceutical industry in Tripoli was the conversation we had with a young employee who decided to leave Athens and make a fresh start in Tripoli.
This is a major life decision that benefits him not only professionally and financially but also on a family level, and at the same time aligns with the government’s major goal of decentralization through investment and well-paid jobs, such as those offered by the Greek pharmaceutical industry.
It is a model that we want to strengthen even further in the coming years, guiding new generations toward real career opportunities. The pharmaceutical industry, which is truly flourishing, creates such opportunities and continually reinforces them.”
The President of the Panhellenic Union of Pharmaceutical Industries (PEF), Mr. Theodoros Tryfon, stated: “We warmly thank you for being here. We are delighted to welcome you to our strategic investments in Tripoli, Arcadia.
The Greek pharmaceutical industry is demonstrating in practice its strategic role as a pillar of growth, innovation, and national resilience. We are implementing a landmark investment program worth 1.8 billion euros nationwide, with the investments in Tripoli serving as a key pillar of this national effort.
These investments translate into thousands of highly skilled jobs, substantially bolster regional development, and create real opportunities for the country’s workforce.
At the same time, they reflect a consistent policy through which your government supports production and strengthens the sector using targeted tools, such as the “clawback” investment offset.
In this way, domestic production will be able to cover up to 70% of the country’s needs for first-line medications, ensuring sufficiency, safety, and better patient access to treatments.
Tripoli is emerging as a strategic hub for pharmaceutical production and research of European significance. At the same time, we are investing in knowledge and education by establishing the first Academy for Professional Training of Pharmaceutical Technicians in Tripoli. Our motto is: “We produce in Greece; we stay in Greece.”
The President and CEO of DEMO S.A. and Vice President of PEF, Mr. Dimitris Demos, stated: “It is with great honor that we welcome government representatives today, as part of an initiative launched by the current government in 2019 that we are now seeing come to fruition with great success.
In November 2021, we announced a strategic investment plan worth 356 million euros, which remains to this day the largest ever implemented in the domestic pharmaceutical industry. The crowning achievement of this plan is the creation of a state-of-the-art production hub in Tripoli, Arcadia—an investment that substantially upgrades the region, creates more than 1,000 jobs, and strengthens the country’s industrial potential.
This investment extends beyond national borders, playing a pivotal role in Europe, as the products we will manufacture will meet 34% of Europe’s needs for penicillin-based drugs and 35% of its needs for injectable chemotherapeutic drugs. In this way, we are actively contributing to ensuring the availability of critical medicines for the European Union, while simultaneously placing Greece on the global map of pharmaceutical raw material production. With four state-of-the-art production facilities—two for chemical raw materials and two for finished products—we are leading our country forward.”
The Chairman of the Board of Directors of Win Medica, Mr. Dimitris Tryfon, stated: “Win Medica is implementing an investment of 80 million euros as part of the ELPEN Group’s overall investment program totaling 350 million euros, with the aim of creating the largest production facility for solid-dose oncology drugs in the country.
The new facility features state-of-the-art, specialized production lines and high-standard research infrastructure, substantially enhancing the country’s self-sufficiency by covering more than 70% of domestic demand for oncology drugs.
At the same time, we are helping to boost exports and the international competitiveness of the Greek pharmaceutical industry, creating more than 300 jobs and actively supporting regional development. “By implementing a modern, environmentally friendly ‘smart factory’ that leverages artificial intelligence technologies, we are investing in a sustainable and innovative production model for the future.”
FARAN’s Chairman and CEO, Mr. Marios Katsikas, stated: “FARAN’s investment in Tripoli substantially strengthens the country’s manufacturing and research base in the field of injectable pharmaceuticals.
The new facility, which meets high technological standards, incorporates advanced production lines for aseptic filling, assembly, and packaging of pre-filled syringes and pharmaceutical pens, and lays the groundwork for the future development of biotechnological drugs.
“With the goal of obtaining certification from leading international organizations, and by implementing modern quality and productivity systems, we are strengthening the outward orientation and international competitiveness of the Greek pharmaceutical industry, while simultaneously creating a significant number of new jobs.”